Cardiac complications associated with the influenza viruses A subtype H7N9 or pandemic H1N1 in critically ill patients under intensive care  by Wang, Jiajia et al.
BO
C
i
H
J
J
T
C
a
A
R
A
A
K
C
H
H
h
1
BARTICLE IN PRESSJID-667; No. of Pages 7
braz j infect dis 2 0 1 6;x  x x(x x):xxx–xxx
www.elsev ier .com/ locate /b j id
The Brazilian Journal of
INFECTIOUS  DISEASES
riginal article
ardiac  complications  associated  with  the
nﬂuenza viruses  A subtype  H7N9  or  pandemic
1N1 in critically  ill  patients  under  intensive  care
iajia Wang, Hua Xu, Xinjing Yang, Daguo Zhao, Shenglan Liu, Xue Sun,
ian-an  Huang, Qiang Guo ∗
he First Afﬁliated Hospital of Soochow University, Department of Medicine, Respiratory, Emergency and Critical Care Medicine, Suzhou,
hina
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 22 February 2016
ccepted 5 October 2016
vailable online xxx
eywords:
ardiac complications
7N9
1N1
a  b  s  t  r  a  c  t
Background and objective: The clinical presentations and disease courses of patients hos-
pitalized with either inﬂuenza A virus subtype H7N9 (H7N9) or 2009 pandemic H1N1
inﬂuenza virus were compared in a recent report, but associated cardiac complications
remain unclear. The present retrospective study investigated whether cardiac complica-
tions in critically ill patients with H7N9 infections differed from those infected with the
pandemic H1N1 inﬂuenza virus strain.
Methods: Suspect cases were conﬁrmed by reverse transcription polymerase chain reaction
assays with speciﬁc conﬁrmation of the pandemic H1N1 strain at the Centers for Disease
Control and Prevention. Comparisons were conducted at the individual-level data of criti-
cally ill patients hospitalized with H7N9 (n = 24) or pandemic H1N1 inﬂuenza virus (n = 22)
infections in Suzhou, China. Changes in cardiac biochemical markers, echocardiography,
and electrocardiography during hospitalization in the intensive care unit were considered
signs of cardiac complications.
Results: The following ﬁndings were more common among the H7N9 group relative to the
pandemic H1N1 inﬂuenza virus group: greater tricuspid regurgitation pressure gradient,
sinus tachycardia (heartbeat ≥ 130 bpm), ST segment depression, right ventricular dysfunc-
tion, and elevated cardiac biochemical markers. Pericardial effusion was more often foundPlease cite this article in press as: Wang J, et al. Cardiac complications associated with the inﬂuenza viruses A subtype H7N9 or pandemic H1N1
in critically ill patients under intensive care. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016.10.005
among pandemic H1N1 inﬂuenza virus patients than in the H7N9 group. In both groups,
most of the cardiac complications were detected from day 6 to 14 after the onset of inﬂuenza
symptoms. Those who developed cardiac complications were especially vulnerable during
the  ﬁrst four days after initiation of mechanical ventilation. Cardiac complications were
reversible in the vast majority of discharged H7N9 patients.
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413-8670/© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Conclusions: Critically ill hospitalized H7N9 patients experienced a higher rate of cardiac
complications than did patients with 2009 pandemic H1N1 inﬂuenza virus infections, with
the  exception of pericardial effusion. This study may help in the prevention, identiﬁcation,
and  treatment of inﬂuenza-induced cardiac complications in both pandemic H1N1 inﬂuenza
virus and H7N9 infections.
© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is
an  open access article under the CC BY-NC-ND license (http://creativecommons.org/Introduction
The emergence of human infections by avian inﬂuenza A sub-
type H7N9 (H7N9) has widened the spectrum of inﬂuenza
A viruses that currently threaten public health.1,2 Reported
complications of H7N9 infection include acute respiratory
distress syndrome (ARDS), shock, acute kidney injury, and
rhabdomyolysis. Yet, less is known about important cardiac
complications related to this virus.2
Acute infection with other strains of inﬂuenza has been
associated with numerous cardiac complications, including
myocardial infarction, myopericarditis, arrhythmias, conges-
tive heart failure, and sudden death.3,4 Rates of cardiac
changes have ranged from 15% to 43% in inﬂuenza A ambula-
tory patients, and from 14% to 75% in hospitalized patients.5–7
The few relevant case reports8–11 indicate that myocardi-
tis and pericarditis may be important cardiac abnormalities
in pandemic H1N1 inﬂuenza virus (pH1N1) infection. In
these case reports, heart dysfunctions were demonstrated by
abnormalities in creatine kinase (CK), CK-isoenzyme MB (CK-
MB), troponin I, electrocardiogram (ECG), and echocardiogram
(ECHO).
It remains unclear whether differing strains of inﬂuenza
affect the cardiovascular system in distinct ways. Accordingly,
we  hypothesized that cardiac complications of acute inﬂuenza
infection may differ among patients hospitalized with H7N9
or pH1N1 strains; and these differences would be magniﬁed in
critically ill patients. The present retrospective study investi-
gated whether cardiac complications in hospitalized critically
ill patients with H7N9 infections differed from those infected
with the pH1N1 strain of inﬂuenza A.
Methods
Date  sources
The Ethics Committee of First Afﬁliated Hospital, College
of Medicine, Soochow University, approved this retrospec-
tive study. All diagnoses of H7N9 (between March 2013 and
July 2014) and pH1N1 (between April 2009 and January 2010)
infection in the patients enrolled in our study were con-
ﬁrmed by reverse transcription polymerase chain reaction
assays from throat swab specimens or respiratory tract sam-Please cite this article in press as: Wang J, et al. Cardiac complications asso
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ples. All patients who  received a diagnosis of pH1N1 infection
also received conﬁrmation of the pandemic H1N1 strain at
the Centers for Disease Control and Prevention. None of the
patients enrolled in this study had a history of preexistinglicenses/by-nc-nd/4.0/).
heart disease, none were pregnant during the inﬂuenza epi-
demic seasons, and all were hospitalized in the intensive care
unit (ICU). Assessments of the clinical condition were con-
ducted upon admission to the ICU. Therapies that were used
before admission were also recorded.
The clinical condition assessment consisted of routine
blood tests, biochemical indicators, computed tomography
(CT), and ratio of partial pressure arterial oxygen (PaO2) to
fraction of inspired oxygen (FiO2) in the H7N9 and pH1N1
groups (i.e., PaO2/FiO2). The Clinical Pulmonary Infection
Score (CPIS) and SMART-COP score were calculated to evalu-
ate the severity of pneumonia.12,13 The Acute Physiology and
Chronic Health Evaluation II (Apache II) and the Sequential
Organ Failure Assessment (SOFA) were also assessed for all
patients to indicate severity of illness.14,15 Data regarding
pre-admission therapies included antiviral drugs, time from
onset to antiviral therapy, and duration and parameters of
mechanical ventilation.
The participants underwent ECG and ECHO examina-
tions within 24 hours of admission, and peripheral blood
was collected to assess cardiac enzyme levels within 48 h.
During the patients’ hospitalizations, potential cardiac com-
plications were assessed routinely with cardiac enzymes,
ECHO, and ECG, and the following were also monitored:
chest pain, hemodynamic instability, tachycardia, pulmonary
crackles, dyspnea, and oxygen saturation. Abnormalities were
reassessed periodically, generally every 3–5 days, until stabi-
lization, resolution, or death.
The transthoracic ECHO evaluations were performed with
a Vivid I Ultrasound scanner (General Electric, Tirat Carmel,
Israel). The image  acquisition and description were performed
by the same sonographer who was blinded to the condition
of the patients, and the results of ECG were interpreted by
the same cardiologist who was also blinded to the condi-
tion. To evaluate the speciﬁcity of adverse cardiac events, we
deﬁned cardiac dysfunction as either ECHO changes or ECG
changes coupled with cardiac biomarkers elevation in the
same patient. We conducted a follow-up at one year of the dis-
charged H7N9 patients, and the results of the ECG and ECHO
were also recorded.
Statistical  analysis
All values are reported as mean ± standard deviation, and fre-
quency data are shown as n (%). Independent sample t-testsciated with the inﬂuenza viruses A subtype H7N9 or pandemic H1N1
dx.doi.org/10.1016/j.bjid.2016.10.005
were used for mean comparisons and the chi-squared test was
used for frequency comparisons between the two groups. All
statistical analyses were performed using SPSS version 13.0
software. A p-value <0.05 was considered signiﬁcant.
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Table 1 – Clinical characteristics of hospitalized patients with H7N9 and pH1N1 upon ICU admission.a
H7N9 pH1N1 p-Value
Subjects 24 22 –
Age, years 58.83 ± 17.52 42.27 ± 16.00 0.002
Male gender, n (%) 17 (70.8) 9 (38.5) 0.041
Any underlying medical condition n (%)b 14 (58.3) 16 (72.7) 0.306
History of hypertension, n (%) 8  (33.3) 6 (27.3) 0.425
Bilateral pneumonia on CT, n (%) 18 (75.0) 20 (90.9) 0.155
PaO2/FiO2 ≤ 200 mmHg, n (%) 17 (70.8) 16 (69.2) 0.887
PaO2/FiO2 ≤ 100 mmHg, n (%) 8 (33.3) 5 (22.7) 0.425
Interval from onset to ICU admission, d 8.50 ± 3.24 5.64 ± 1.79 0.01
Interval from onset to antiviral therapy, d 7.04 ± 2.23 5.86 ± 2.25 0.082
Oseltamivir treatment, n (%) 24 (100) 20 (90.9) 0.168
Mechanical ventilation, n (%) 10 (41.7) 7 (31.8) 0.489
Interval of MV before admission, d 2.56 ± 2.35 1.71 ± 1.89 0.542
ARDS, n (%) 7 (29.2) 3 (13.6) 0.202
Septic shock, n (%) 1 (4.5) 2 (8.3) 0.603
PEEP value, cmH2O 11.44 ± 4.69 6.14 ± 2.04 0.015
PPLAT value, cmH2O 23.56 ± 7.27 17.0 ± 4.44 0.044
CPIS 5.0 ± 1.67 5.73 ± 1.91 0.175
SMART-COP 3.13 ± 1.36 3.64 ± 1.43 0.221
APACHE-II 19.61 ± 5.46 20.44 ± 6.74 0.686
SOFA 7.67 ± 2.59 7.39 ± 2.66 0.753
a Data are presented as mean ± standard deviation or n (%).
b Such as hypertension, diabetes, chronic hepatitis, chronic respiratory disease, chronic kidney disease, rheumatoid arthritis, related to surgery,
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esults
atient  characteristics
his study included 46 critically ill patients admitted to the
CU, 24 with H7N9 (ages 58.83 ± 17.52 y) and 22 with pH1N1
42.27 ± 16.00 y) infections (Table 1). The percentage of men
n the H7N9 group (70.8%) was higher than that of the pH1N1
roup (38.5%). The two groups were statistically comparable
ith regard to underlying medical conditions, PaO2/FiO2, and
ilateral lung involvement on CT.
reatments
reatment dates, with respect to viral-load kinetics, were
vailable for patients who had received antiviral agents.
he H7N9 and pH1N1 groups were similar regarding the
umber of days from onset of symptoms to antiviral therapy,
nd also the number of days on mechanical ventilation
rior to ICU admission (Table 1). Antiviral therapy consisted
f oseltamivir at a daily dose of 150 mg,  for patients who
eceived it. Every H7N9 patient in the H7N9 group received
ntiviral therapy, compared to only 90.9% of pH1N1 patients.
echanical ventilation on admission was required by 41.7%
nd 31.8% of the H7N9 and pH1N1 patients, respectively.
ositive end-expiratory pressure (PEEP) and plateau airway
ressure (PPLAT) values of the H7N9 patients were signiﬁcantly
igher than that of the pH1N1 group.Please cite this article in press as: Wang J, et al. Cardiac complications asso
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everity  of  illness
PIS, SMART-COP, APACHE-II, and SOFA scores reﬂect the
everity of pneumonia and organ injury. There were nosigniﬁcant differences in CPIS, SMART-COP, APACHE-II, or
SOFA scores between the H7N9 and pH1N1 patients (Table 1).
The routine peripheral blood results also showed no signiﬁ-
cant differences between these groups (Table 2).
Cardiac  events
The incidence of cardiac events was 70.8% and 45.5% in the
H7N9 and pH1N1 groups, respectively. The rates for the fol-
lowing elevated cardiac biomarkers were signiﬁcantly higher
among H7N9 patients than in the pH1N1 group (Table 3):
troponin I, CK, CK-MB, and brain natriuretic peptide (BNP).
Pericardial effusion was detected signiﬁcantly less in the H7N9
group than the pH1N1 group.
The presence of any ECG changes was identiﬁed more  fre-
quently in H7N9 patients than in pH1N1 patients (Table 4);
the rates of sinus tachycardia and ST segment depression
were signiﬁcantly higher in H7N9 patients. The median time
interval from onset of inﬂuenza infection to identiﬁcation of
decreased ejection fraction was 10.5 days and 9.0 days in the
H7N9 and pH1N1 patients, respectively (Table 5). The median
time interval from inﬂuenza onset to cardiac biomarkers (tro-
ponin I, CK, CK-MB, and BNP), ECHO, and ECG abnormality in
the H7N9 and pH1N1 groups were 8–11 days and 6–14 days,
respectively.
The median time interval from initiation of mechanical
ventilation to a decrease in ejection fraction in the H7N9 group
was 1.5 days (Table 6). In addition, the changes in cardiac
biomarkers, ECG, and another ECHO index were found lessciated with the inﬂuenza viruses A subtype H7N9 or pandemic H1N1
dx.doi.org/10.1016/j.bjid.2016.10.005
than four days (median time) after initiation of mechanical
ventilation. We could not calculate the median time from
mechanical ventilation to the above index changes due to
insufﬁcient data in the pH1N1 group. Data regarding cardiac
Please cite this article in press as: Wang J, et al. Cardiac complications associated with the inﬂuenza viruses A subtype H7N9 or pandemic H1N1
in critically ill patients under intensive care. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016.10.005
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Table 2 – Laboratory results of hospitalized patients with H7N9 and pH1N1 upon ICU admission.a
H7N9 pH1N1 P
Subjects 24 22 –
Leukopenia, n (%) 3 (12.5) 6 (27.3) 0.207
Neutropenia, n (%) 1 (4.2) 2 (9.1) 0.499
Lymphopenia, n (%) 21 (87.5) 16 (72.7) 0.207
Thrombocytopenia, n (%) 5  (20.8) 7 (31.8) 0.397
Hypoproteinemia, n (%) 10  (41.7) 12 (54.5) 0.382
Elevated creatinine, n (%) 4 (16.7) 3 (13.6) 0.775
Elevated nitrogen, n (%) 11 (45.8) 7 (31.8) 0.331
Elevated ALT, n (%) 8 (33.3) 7 (31.8) 0.913
Elevated AST, n (%) 19 (79.2) 12 (46.2) 0.075
Acidosis, n (%) 3 (12.5) 2 (9.1) 0.711
White cell count, ×109 L−1 7.70 ± 5.03 6.50 ± 3.26 0.347
Neutrophil count, ×109 L−1 6.86 ± 4.78 5.33 ± 3.07 0.207
Lymphocyte count, ×109 L−1 0.59 ± 0.40 0.76 ± 0.47 0.190
Platelet count, ×109 L−1 164.58 ± 65.15 137.27 ± 57.96 0.140
Albumin, g/L 30.76 ± 5.03 31.38 ± 6.22 0.709
Prealbumin, mg/L 86.9 ± 86.79 117.60 ± 53.20 0.160
Creatinine, mol/L 85.13 ± 34.50 128.17 ± 218.99 0.347
Urea nitrogen, mmol/L 9.21 ± 7.52 6.52 ± 5.12 0.167
ALT, U/L 50.15 ± 29.92 43.03 ± 40.24 0.497
AST, U/L 77.84  ± 48.42 48.35 ± 41.89 0.073
a Data are presented as mean ± standard deviation or n (%).
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Table 3 – Cardiac biomarkers and echocardiography changes in hospitalized patients with H7N9 and pH1N1.a
H7N9 pH1N1 p-Value
Subjects 21 20 –
Elevated troponin I, n (%) 7 (33.3) 1 (5.0) 0.022
Elevated CK, n (%) 14 (66.7) 7 (35.0) 0.043
Elevated CK-MB, n (%) 10 (47.6) 3 (15.0) 0.025
Elevated BNP, n (%) 9 (42.9) 3 (15.0) 0.05
Decreased EF value, n (%) 4 (19.0) 2 (10.0) 0.413
Elevated TRPG, n (%) 15 (71.4) 2 (10.0) 0.000
Pericardial effusion, n (%) 1 (4.7) 7 (35.0) 0.017
RV dilatation or systolic dysfunction, n (%) 6 (28.6%) 1 (5.0%) 0.045
a Data are presented as n (%).
RV, right ventricular.
Table 4 – ECG changes in hospitalized patients with H7N9 and pH1N1.a
H7N9 pH1N1 P
Subjects, n 23 22 –
Any abnormal ECG 19 (82.6) 12 (54.5) 0.042
Sinus tachycardiab 10 (43.5) 3 (13.6) 0.027
Ventricular tachycardia 5 (21.7) 2 (9.1) 0.242
Atrial premature beat 2 (8.7) 0 (0) 0.157
Ventricular premature beat 1 (4.3) 1(4.5) 0.974
Atrial ﬁbrillation 3 (13.0) 3 (13.6) 0.953
Atrioventricular block 1 (4.3) 0 (0) 0.323
Intraventricular block 3  (13.0) 0 (0) 0.08
Sinus arrhythmia 1 (4.3) 1 (4.5) 0.974
ST segment depression 10 (43.5) 3 (13.6) 0.027
ST segment elevation 3 (13.0) 1 (4.5) 0.317
T wave inversion 3 (13.0) 2 (4.5) 0.673
T wave ﬂattening 5 (21.7) 2 (4.5) 0.242
Q wave 0 (0) 1 (4.5) 0.301
Pulmonary p wave 1 (4.3) 1 (4.5) 0.974
a Data are presented as n (%), unless indicated otherwise.
b Heartbeat ≥ 130 bpm
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Table 5 – Interval (days) from onset of symptoms to development of adverse cardiac events in patients with H7N9 and
pH1N1.a
H7N9 pH1N1 p-Value
Elevated troponin I 9.5 (3.75–11.25) 7b NA
Elevated CK 8.0 (7.0–9.5) 6.0 (3–10) 0.056
Elevated CK-MB 8.0 (4.75–10) 14.0 (7.0–21.0) 0.516
Elevated BNP 10 (8.75–20.0) 10 (7–12) 0.547
Decreased EF 10.5 (7.75–26.75) 9.0 (7–11) 0.634
RV dilatation or systolic dysfunction 11.0 (6.25–20.5) 12b NA
Elevated TRPG value 10.0 (8.0–11.0) 13.0 (12–14) 0.096
ECG abnormalities 8.0 (6.5–10.0) 8.5 (6.75–21.5) 0.416
a Data are presented as median (interquartile range).
b Only one patient presented abnormalities.
EF, ejection fraction; NA, not applicable due to insufﬁcient data; RV, right ventricular.
Table 6 – Interval (days) from mechanical ventilation initiation to development of adverse cardiac events in patients with
H7N9 and pH1N1.a
H7N9 pH1N1 p-Value
Elevated troponin I 1.5 (1–4.75) 1b NA
Elevated CK 2.5 (1–5.0) 6b NA
Elevated CK-MB 1 (1–2.5) NA NA
Elevated BNP 2.0 (1–10.0) NA NA
Decreased EF 1.5 (1–19.25) NA NA
RV dilatation or systolic dysfunction 3.5 (1.75–6.75) 6b NA
Elevated TRPG 2.0 (1–5.0) NA NA
ECG abnormalities 2.0 (1.0–9.25) 1 (1–16) 0.79
a Data are presented as median (interquartile range).
b Only one patient presented abnormalities.
EF, ejection fraction; NA, not applicable due to insufﬁcient data; RV, right ventricular.
Table 7 – Clinical characteristics of patients with H7N9 and PH1N1 during hospitalization.a
H7N9 pH1N1 p-Value
Subjects, n 24 22
Mechanical ventilation, n (%) 14 (58.3) 7 (31.8) 0.071
Septic shock, n (%) 7 (29.2) 2 (9.1) 0.086
ARDS, n (%) 14 (58.3) 6 (27.3) 0.034
Maximum PEEP, cmH2O 13.83 ± 5.04 8.43 ± 5.29 0.026
Maximum PPLAT, cmH2O 28.67 ± 6.8 22.29 ± 6.18 0.042
Minimum PaO2/FiO2 110.44 ± 76.68 161.25 ± 69.14 0.062
Ventilator d 24.18 ± 17.78 10.56 ± 9.83 0.045
ICU stay, d 40.23 ± 27.67 20.86 ± 19.59 0.01
other
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gMortality, n (%) 9 (37.5) 
a Data are presented as mean ± standard deviation unless indicated 
nzymes and ECHO were not available for three H7N9 patients
nd two pH1N1 patients, and ECG data was not available for
ne H7N9 patient. For both groups, most of the cardiac com-
lications were detected between days six and 14 after onset
f symptoms. The ﬁrst four days after initiation of mechanical
entilation showed the highest incidence of cardiac complica-
ions during hospitalization.
linical  characteristics  and  clinical  outcomes
ll of the 46 patients in this study were directly admitted to thePlease cite this article in press as: Wang J, et al. Cardiac complications asso
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CU (Table 7). Fourteen H7N9 patients (58.3%) and six pH1N1
atients (27.3%) suffered from ARDS. Of the patients with
espiratory failure, 58.3% and 31.8% of the H7N9 and pH1N1
roups, respectively, required invasive mechanical ventilation.3 (13.6) 0.066
wise.
Notably, the number of days on mechanical ventilation, and
the maximum PEEP and PPLAT values, were signiﬁcantly higher
in the H7N9 group compared with the pH1N1 group, and the
minimum PaO2/FiO2 was lower. The mean ICU length of stay
of the H7N9 patients was signiﬁcantly longer than that of the
pH1N1 group (p = 0.01). The mortality rates of the two  groups
were similar (p = 0.066).
Follow-up
The one-year follow-up was completed for nine of 11 dis-ciated with the inﬂuenza viruses A subtype H7N9 or pandemic H1N1
dx.doi.org/10.1016/j.bjid.2016.10.005
charged H7N9 patients who had evidence of one or more
cardiac complications during hospitalization. One subject was
lost to follow-up and one died of renal failure. Cardiac abnor-
malities that were observed during hospitalization primarily
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included tachycardia, atrial ﬁbrillation, and ST changes. All
of these parameters had returned to normal at follow-up.
An elevated tricuspid regurgitation pressure gradient (TRPG)
was found in four of these individuals during hospitalization,
which returned to normal in three of them.
Discussion
This retrospective study investigated whether the cardiac
complications of patients admitted to the ICU with H7N9
infections differed from those infected by the pH1N1 strain
of inﬂuenza A. We  found that acute H7N9 infection can result
in severe cardiac complications, and a higher proportion of
H7N9 patients experienced cardiac complications, except for
pericardial effusion, than did the patients with 2009 pH1N1
infections. Most cardiac complications were detected between
days six and 14 in both groups after onset of disease, and
the ﬁrst four days of mechanical ventilation appeared to be
a period of greater risk for the development of cardiac com-
plications in susceptible individuals. The results of patient
follow-up indicate that cardiac complications are reversible
in the majority of H7N9 patients who  outlived the infection.
Collectively, these data suggest that cardiac complications
associated with acute inﬂuenza H7N9 and pH1N1 infections
differ. These differences may help clinicians identify and treat
these complications in a timely manner.
The clinical data of the H7N9 and pH1N1 groups obtained
upon ICU admission were compared in detail. The two groups
were similar except for age, gender ratio, number of days from
onset of symptoms to admission, and PEEP and PPLAT values.
Although the time between the onset of the disease and ICU
admission was statistically higher in the H7N9 group than
in the pH1N1, the treatment strategy before ICU admission
was similar. Furthermore, the groups were also comparable for
severity of pneumonia or organ injury according to the CPIS,
SMART-COP, APACHE-II, and SOFA scoring systems. Accord-
ingly, we  consider that the lag time between onset of the
disease and ICU admission had little inﬂuence on the high
incidence of cardiac complications in H7N9 group.
The clinical features of hospitalized patients with H7N9
infection were generally similar to those of patients with
pH1N1 infection. Patients usually presented with early fever,
cough, and sputum production, with rapid progression to
severe pneumonia, moderate-to-severe ARDS, and septic
shock. Multiple biomarkers of myocardial injury and cardiac
dysfunction were monitored in the present study, including
CK, CK-MB, troponin-I, and BNP. These are minimally inva-
sive tests with high speciﬁcity, sensitivity, and diagnostic and
prognostic implications.16,17 Notably, in the present study the
above biomarkers were at higher levels in the H7N9 group than
the pH1N1 group.
Echocardiography is considered an ideal tool in clinical
practice to evaluate cardiac function and anatomic struc-
ture. In a study by Brown et al.,18 right heart dilation was
observed in 50–80% of critically ill PH1N1 patients, systolicPlease cite this article in press as: Wang J, et al. Cardiac complications asso
in critically ill patients under intensive care. Braz J Infect Dis. 2016. http://
dysfunction in 23%, and left heart failure in 17%. However,
in our present cohort, the prevalence of ECHO abnormalities
in pH1N1 patients was lower. It has been reported that
ARDS and mechanical ventilation can contribute to cardiac 6;x x x(x x):xxx–xxx
insufﬁciency.19,20 In the present study, the rates of mechanical
ventilation use and ARDS was lower than the rates reported
by Brown et al. (31.8% cf. 91% and 27.3% cf. 83%, respectively)
which, in part, accounts for differences in the rates of cardiac
complications.
To date, the prevalence of ECHO abnormalities in H7N9
patients has not been characterized. In the present study, the
H7N9 patients experienced higher rates of both right ven-
tricular dysfunction and TRPG overload in the H7N9 group
compared with the pH1N1 group. This may be partly due
to the higher prevalence of ARDS in the H7N9 group, and
higher PEEP requirements and PPLAT administrated. Over  50%
of the patients in each group had abnormal ECG results, most
of which were benign and nonspeciﬁc (tachycardia, atrial
ﬁbrillation, and ST segment changes). The degree of sinus
tachycardia and ST segment depression was higher in the
H7N9 group than in the pH1N1 group, suggesting a higher rate
of myocardial ischemia. In a study by Liu et al.,21 congestive
heart failure was identiﬁed in ﬁve of the 10 fatal H7N9 cases
in Zhejiang province of China. In another study, left ventri-
cular failure was noted in two of six hospitalized H7N9 cases
in Shanghai, China.22 A decrease in left ventricular ejection
fraction was found in four of the 21 H7N9 patients, while left
ventricular dilatation was not found in our cohort.
There has not been a consensus regarding myocardial
involvement in inﬂuenza infection, because the diagnostic
criteria and patients’ clinical conditions have varied across
studies.3,23 In two ICU cohorts of patients with pH1N1 infec-
tion, the prevalence of cardiovascular complications was 34%
and >50%, respectively.23,24 In the present study, the overall
prevalence of cardiac complications in the H7N9 and pH1N1
groups was 70.8% and 45.5%, respectively. The mechanism of
cardiac involvement in inﬂuenza infection is thought to be
multifactorial, including fever, vasodilatation, hypovolemia,
hypoxia, proinﬂammatory cytokines, procoagulant effects,
and direct invasion of the inﬂuenza virus.25,26
Apart from ARDS and the associated mechanical ventila-
tion setting, the higher incidence of septic shock and older age
of the H7N9 group may have inﬂuenced the higher incidence
of cardiac complications in that group.27,28 Cardiac involve-
ment in inﬂuenza has been reported to occur usually between
four and nine days after the onset of inﬂuenza symptoms.29
This is similar to the median interval from onset to identi-
ﬁcation of cardiac events in our present study for both the
H7N9 and pH1N1 groups (8–11 days and 6–14 days, respec-
tively). We  also noted that more  than half of the H7N9 patients
had cardiac events within four days after mechanical ventila-
tion was initiated. Unfortunately, due to the small cohort, the
statistical power of this observation for the pH1N1 patients is
limited. The possibilities of existing heart disease and cardiac
complications in H7N9 infection should be considered in the
management of the disease, due to its associated increased
mortality.23,30 Our present report of the substantial mortality
associated with H7N9 infection conﬁrms that the manage-
ment of cardiac complications is an important issue.
In conclusion, this study shows that there are many
indications of cardiac complications in inﬂuenza infections.ciated with the inﬂuenza viruses A subtype H7N9 or pandemic H1N1
dx.doi.org/10.1016/j.bjid.2016.10.005
A higher proportion of H7N9 patients experienced cardiac
dysfunction compared with patients with pH1N1 infections,
with the exception of pericardial effusion. In both groups,
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ost of the cardiac complications were detected from six to
4 days after the onset of inﬂuenza symptoms. The ﬁrst four
ays after the initiation of mechanical ventilation seemed
o be the period in which susceptible patients were most
ulnerable to cardiac complications. However, for the vast
ajority of H7N9 patients who outlived the infection, cardiac
omplications appear to be reversible. We identiﬁed severe
ardiac complications in critically ill patients with either H7N9
r pH1N1 infections. Recognizing differences in inﬂuenza-
ssociated cardiac complications between pH1N1 and H7N9
trains may help clinicians to identify and treat these com-
lications early. We  hope that our ﬁndings may help in the
revention, early identiﬁcation, and treatment of inﬂuenza-
nduced cardiac complications in pH1N1 and H7N9 infections.
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